Pham Quang X sold $22K of CVKD
Pham Quang X (Chairman and CEO) sold 7,400 shares of Cadrenal Therapeutics, Inc. (CVKD) at $3.03 on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure confirms an insider open-market sale (7,400 shares) at a stated price, but provides no new business or financial guidance in the text.
Market read
Primarily a sentiment/positioning datapoint; likely limited trading impact absent additional catalysts.
What to watch
Traders may overreact to insider sales; without concurrent fundamentals (earnings, trial, financing, or regulatory updates), the signal is typically weak.
Background
The article is an SEC Form 4 insider transaction for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
SEC Form 4 shows CVKD chairman/CEO Pham Quang X sold 7,400 shares on 2026-06-29 at $3.03 via a 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless accompanied by other company-specific news.
The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change in the text.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerCadrenal Therapeutics, Inc.
Company whose insider transaction is disclosed on SEC Form 4.
- insiderPham Quang X
Chairman and CEO and 10% owner who sold shares under a pre-arranged 10b5-1 plan.
